Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at financialmarketmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. FinancialMarketMovers.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent AMN Stock Price: $68.50
Summary: AMN Healthcare Services is a travel healthcare staffing company. It recruits and places nurses, physicians, and other healthcare professionals in travel or permanent assignments in acute-care facilities, physician practice groups, and other healthcare facilities. The company currently reports through three segments: Nurse and Allied Solutions, Locum Tenens Solutions and Other Workforce Solutions. Nurse and Allied Solutions provides services for acute-care facility, permanent staff nurses for medical practice and experienced home care nurse staffing, interim nurse leaders. Locums Tenens Solutions physicians can act during staffing gaps created by vacancies, vacations and periods of high demand. Meanwhile, Workforce Solutions offers the most comprehensive suite of innovative workforce solutions, ranging from traditional staffing and recruitment to managed services programs, vendor management systems, in-house resource pool management and recruitment process outsourcing.
Brian McKenna analyst at JMP Securities reiterates coverage on AMN Healthcare Services (AMN) stock in the energy sector with a Buy rating and has set AMN's stock price target at $85.
TipRanks.com reports that AMN Healthcare Services currently has 5 analysts offering 12-month price targets on AMN and the consensus is a Moderate Buy rating with an average stock price target of $80.20. The most recent AMN stock price we have is $68.50 and we are not making any AMN forecasts at this time.
In addition, TradingView issued a Sell rating for AMN over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AMN. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on AMN, please click here >>
REPRO-MED Systems, KRMD
Recent KRMD Stock Price: $2.28
Summary: Repro-Med Systems Inc. is engaged in the design and manufacture of medical devices directing resources to the global markets for emergency medical products and infusion therapy.
Alexander Nowak analyst at Craig-Hallum reiterates coverage on REPRO-MED Systems (KRMD) stock in the energy sector with a Buy rating and has not provided KRMD's stock price target.
TipRanks.com reports that REPRO-MED Systems currently has 4 analysts offering 12-month price targets on KRMD and the consensus is a Strong Buy rating with an average stock price target of $3.50. The most recent KRMD stock price we have is $2.28 and we are not making any KRMD forecasts at this time.
In addition, TradingView issued a Sell rating for KRMD over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on KRMD. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on KRMD, please click here >>
Arvinas Holding Company, ARVN
Recent ARVN Stock Price: $30.30
Summary: Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.
Akash Tewari analyst at Jefferies reiterates coverage on Arvinas Holding Company (ARVN) stock in the energy sector with a Buy rating and has set ARVN's stock price target at $40.
TipRanks.com reports that Arvinas Holding Company currently has 5 analysts offering 12-month price targets on ARVN and the consensus is a Strong Buy rating with an average stock price target of $60.00. The most recent ARVN stock price we have is $30.30 and we are not making any ARVN forecasts at this time.
In addition, TradingView issued a Strong Buy rating for ARVN over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ARVN. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ARVN, please click here >>
Cytokinetics, CYTK
Recent CYTK Stock Price: $33.46
Summary: Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.
Akash Tewari analyst at Jefferies reiterates coverage on Cytokinetics (CYTK) stock in the energy sector with a Buy rating and has set CYTK's stock price target at $75.
TipRanks.com reports that Cytokinetics currently has 5 analysts offering 12-month price targets on CYTK and the consensus is a Strong Buy rating with an average stock price target of $66.80. The most recent CYTK stock price we have is $33.46 and we are not making any CYTK forecasts at this time.
In addition, TradingView issued a Buy rating for CYTK over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CYTK. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on CYTK, please click here >>
Olema Pharmaceuticals, OLMA
Recent OLMA Stock Price: $11.72
Summary: Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California.
Emily Bodnar analyst at H.C. Wainwright reiterates coverage on Olema Pharmaceuticals (OLMA) stock in the energy sector with a Buy rating and has set OLMA's stock price target at $28.
TipRanks.com reports that Olema Pharmaceuticals currently has 5 analysts offering 12-month price targets on OLMA and the consensus is a Strong Buy rating with an average stock price target of $24.80. The most recent OLMA stock price we have is $11.72 and we are not making any OLMA forecasts at this time.
In addition, TradingView issued a Sell rating for OLMA over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on OLMA. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on OLMA, please click here >>
Vertex Pharmaceuticals, VRTX
Recent VRTX Stock Price: $353.46
Summary: Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.
Evan Seigerman analyst at BMO Capital reiterates coverage on Vertex Pharmaceuticals (VRTX) stock in the energy sector with a Buy rating and has set VRTX's stock price target at $415.
TipRanks.com reports that Vertex Pharmaceuticals currently has 4 analysts offering 12-month price targets on VRTX and the consensus is a Moderate Buy rating with an average stock price target of $394.75. The most recent VRTX stock price we have is $353.46 and we are not making any VRTX forecasts at this time.
In addition, TradingView issued a Sell rating for VRTX over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on VRTX. financialmarketmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on VRTX, please click here >>
The editors at financialmarketmovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinancialMarketMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinancialMarketMovers.com.
==============================================================================
